Viewing Study NCT02611960


Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2026-02-25 @ 4:56 PM
Study NCT ID: NCT02611960
Status: COMPLETED
Last Update Posted: 2023-07-13
First Post: 2015-11-19
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Nasopharyngeal Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None Programmed Death-Ligand 1 (PDL1, PD-L1) View